The Relation Between Adiposity, Inflammation, Glycaemia and Iron Absorption
NCT ID: NCT03310203
Last Updated: 2019-01-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
126 participants
INTERVENTIONAL
2017-09-27
2018-12-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Central and Peripheral Adiposity and Iron Absorption
NCT03642223
Evaluation of Body Iron Stores in Overweight Healthy Volunteers
NCT02304874
Very-low-density-lipoprotein Triglyceride (VLDL-TG) Uptake in Visceral Fat
NCT00893893
Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2
NCT06694012
Body Composition and Very-Low-Density-Lipoprotein-Triglycerides (VLDL-TG) Kinetics
NCT00646698
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
During the first phase, overweight/obese subjects with a BMI 28-35 Kg/m2 will be invited to a screening. At the screening, anthropometrics (weight, height, waist circumference) and body composition (using BIA and DEXA) will be measured. Based on the subject's distribution of body fat, those who have a predefined % body fat between 45-55% will be invited to join the study and they would fall into one of the following two groups:
* 42 subjects with \>43% fat in the android sector (area from the pelvis to 20% of the distance between the pelvis and the neck cuts) according to the DEXA results (central adiposity) would be recruited
* 42 subjects with \<43% fat in the android sector according to DEXA (peripheral adiposity) would be recruited.
2. Lean subjects At the same time, anthropometric (weight, height, waist circumference) and body composition (using BIA and DEXA) measurement will be conducted on interested lean subjects (BMI 20-25).
Overnight fasted subjects:
At T0:
There will be a determination of the type and degree of obesity through the measurement of weight, height, BMI, and WC, followed by both BIA screening and DEXA scan to obtain a more detailed image about the status of the participant.
At T1:
A fasting blood sample of 10 ml (4 ml EDTA coated tubes, 6 ml uncoated tubes) will be drawn to measure the inflammatory status, glycaemia, and iron levels of the participant by determining CRP, alpha-glycoprotein, hepcidin, ferritin, TfR, TIBC, HbA1c, insulin, FPG, serum iron, CBC and lipid profile.
After this blood test, the subject will be given a meal including 57Fe (6 mg iron as FeSO4).
At T2:
A second venous blood sample of 10 ml (4 ml EDTA coated tubes, 6 ml uncoated tubes) will be drawn for analysis of hemoglobin and erythrocyte isotopic composition as well as for the determination of serum ferritin, transferrin receptor, C-reactive protein, alpha-glycoprotein and hepcidin.
At T3:
A third venous blood sample of 10 ml (4 ml EDTA coated tubes, 6 ml uncoated tubes) will be drawn to measure the level of glucose, insulin, TG, FFA, TIBC and serum iron. This blood test will be an indicator of the level of glycaemia and iron appearance in the blood of the subject through the earlier ingestion of OGTT and oral iron load.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Obese women: central obesity
OGTT with iron
Iron
Labelled iron
Obese women: peripheral obesity
OGTT with iron
Iron
Labelled iron
Lean women
OGTT with iron
Iron
Labelled iron
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Iron
Labelled iron
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ETH Zurich (Switzerland)
OTHER
American University of Beirut Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Omar Obeid, PhD
Role: PRINCIPAL_INVESTIGATOR
American University of Beirut Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
American University of Beirut
Beirut, , Lebanon
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NUT:OO:23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.